Performance of the pegfilgrastim on-body injector as studied with placebo buffer in healthy volunteers.

CONCLUSIONS: The pegfilgrastim OBI was well tolerated, and deliveries of placebo buffer were successful 98.3% of the time. The generalizability of these results may be limited by the conduct of this study in healthy subjects in a controlled environment. PMID: 27819161 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/27819161?dopt=Abstract

Source: Current Medical Research and Opinion - November 9, 2016 Category: Research Tags: Curr Med Res Opin Source Type: research